Merck's $9.5 Cubist buyout got off to a rocky start when a U.S. court nixed all but one patent covering top-seller Cubicin. And now, it'll be up to brand-new FDA approval Zerbaxa to turn things around.
Cubist Pharmaceuticals picked up FDA approval for its latest antibiotic contender, a potential blockbuster whose promise helped bring Merck to the table with a $9.5 billion buyout offer.
A war of words has broken out over the past week between Eli Lilly's Elanco animal health division and the company's hometown newspaper, the Indianapolis Star. At issue is an overriding question that weighs on the minds of pet owners worldwide: Are medications for dogs and cats really safe?
GlaxoSmithKline rolled out data from a hefty Phase III study showing that its shingles-fighting candidate cut the risk of that disease by 97.2% in adults aged 50 and older, compared with placebo.
Further beefing up its rapidly growing pipeline for new cancer drugs, Merck has stepped in to buy out Switzerland's OncoEthix in a deal worth upward of $375 million. And the Big Pharma player is paying a hefty premium for a BET inhibitor that was in-licensed from Mitsubishi Tanabe just two years ago.
Merck's Gardasil follow-up is here, meaning blockbuster sales are likely on the way. But they'll come at the expense of the previous iteration.
Merck won the FDA's blessing for a next-generation HPV vaccine designed to usurp Gardasil, putting it in line for billions in revenue.
Investigators have suspended a Phase I study of NewLink Genetics' Ebola virus vaccine just weeks after Merck stepped in to license it, citing a safety issue that could delay the pharma giant's plans to quickly ramp up production.
Indonesia is one of those emerging markets that has pressured outside companies to produce locally and companies like Pfizer, Merck and Fresenius Kabi have all built or expanded plants there in recent years. But the government, which controls some of the players, is taking steps to improve efficiency in the domestic market, pushing for a merger that ties the manufacturing expertise of one company to the supply chain strength of another.
Merck's Gardasil follow-up is here, meaning blockbuster sales figures are likely on the way. But the bad news is that they'll come at the expense of the world's second-best-selling shot.